Abstract
The Public Can Trust the FDA's Vaccine Review Process.
Highlights
With the upcoming November election and calls by President Trump for 1 or more vaccines for coronavirus disease 2019 (COVID-19) to be ready before the end of the year, if not by the election, many have started to wonder whether the US Food and Drug Administration (FDA) can withstand this type of political pressure
Noting the FDA’s historically robust review process and decades of experience with regulatory flexibility in multiple product areas, the answer is an unqualified vote of support for the FDA
The public should be reassured that vaccines approved by the FDA will have been subject to the same strenuous reviews that have characterized the agency’s previous reviews
Summary
With the upcoming November election and calls by President Trump for 1 or more vaccines for coronavirus disease 2019 (COVID-19) to be ready before the end of the year, if not by the election, many have started to wonder whether the US Food and Drug Administration (FDA) can withstand this type of political pressure. The Public Can Trust the FDA’s Vaccine Review Process Noting the FDA’s historically robust review process and decades of experience with regulatory flexibility in multiple product areas, the answer is an unqualified vote of support for the FDA.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
